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Summary
Background: Cells undergoing apoptosis are known tomodu-
late their tissue microenvironments. By acting on phagocytes,
notably macrophages, apoptotic cells inhibit immunological
and inflammatory responses and promote trophic signaling
pathways. Paradoxically, because of their potential to cause
death of tumor cells and therebymilitate againstmalignant dis-
ease progression, both apoptosis and tumor-associated mac-
rophages (TAMs) are often associated with poor prognosis in
cancer.We hypothesized that, in progression ofmalignant dis-
ease, constitutive loss of a fraction of the tumor cell population
through apoptosis could yield tumor-promoting effects.
Results: Here, we demonstrate that apoptotic tumor cells
promote coordinated tumor growth, angiogenesis, and accu-
mulation of TAMs in aggressive B cell lymphomas. Through
unbiased ‘‘in situ transcriptomics’’ analysis—gene expression
profiling of laser-captured TAMs to establish their activation
signature in situ—we show that these cells are activated10Co-first author
*Correspondence: chris.gregory@ed.ac.uk
This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).to signal via multiple tumor-promoting reparatory, trophic,
angiogenic, tissue remodeling, and anti-inflammatory path-
ways. Our results also suggest that apoptotic lymphoma cells
help drive this signature. Furthermore, we demonstrate that,
upon induction of apoptosis, lymphoma cells not only activate
expression of the tumor-promoting matrix metalloproteinases
MMP2 and MMP12 in macrophages but also express and pro-
cess these MMPs directly. Finally, using a model of malignant
melanoma, we show that the oncogenic potential of apoptotic
tumor cells extends beyond lymphoma.
Conclusions: In addition to its profound tumor-suppressive
role, apoptosis can potentiate cancer progression. These re-
sults have important implications for understanding the funda-
mental biology of cell death, its roles in malignant disease, and
the broader consequences of apoptosis-inducing anti-cancer
therapy.
Introduction
Cells dying by apoptosis are rapidly engulfed by phagocytes.
Histologically, apoptotic cells are most commonly co-local-
ized with macrophages, and the phagocytic response is
accompanied by production of anti-inflammatory and trophic
factors [1–4]. Similar tissue-reparatory activation states are
typical of tumor-associated macrophages (TAMs), and there
is growing recognition that TAMs often promote tumor
growth and progression by facilitating angiogenesis, matrix re-
modeling, and metastasis and by suppressing anti-tumor im-
munity. Thus, TAM accumulation and activation are generally
associated with poor prognosis. The pro-tumor properties of
TAMs have been studied extensively in certain malignancies
[5–7], but the mechanisms underlying oncogenic activation
of TAMs are not fully understood.
Apoptosis has a defined purpose in preventing tumorigen-
esis [8], but, paradoxically, high incidence of apoptosis is
linked to aggressive disease in multiple malignancies [9–14].
Indeed, cell loss is significant in aggressive tumors [9], and it
is notable that programmed cell death can generate reparative
and regenerative tissue responses such as angiogenesis and
compensatory proliferation that have strong potential to be
causally associated with tumor progression [4, 15].
Given the poor prognostic indications of both apoptosis and
TAM content in malignant disease and the established func-
tional relationship between apoptosis andmacrophage activa-
tion, we hypothesized that loss of tumor cells by apoptosis and
associatedmacrophage activation could facilitate progression
of malignant disease. Here, we show that apoptosis promotes
tumor growth, angiogenesis, and accumulation of pro-onco-
genic TAMs in aggressive non-Hodgkin’s lymphoma (NHL).
Results
Suppression of Apoptosis in Lymphoma Cells Constrains
Tumor Cell Proliferation In Vivo
We initially studied a xenograft model of an aggressive ‘‘starry-
sky’’ NHL, Burkitt’s lymphoma (BL), in which apoptotic tumor
cells are common and frequently observed in association
with the starry-sky TAMs (SS-TAMs, so called because
578they appear histologically as ‘‘stars’’ in a ‘‘sky’’ of tumor cells)
that accumulate in these tumors [16]. We used BL cell lines
thatphenotypically resemble the tumorbiopsycells fromwhich
theywere derived, including the capacity to undergo apoptosis
constitutively [17]. BL xenografts in severe combined immuno-
deficiency (SCID) mice closely recapitulate the starry-sky
histological picture of the human lymphoma (Figure 1A).
Apoptosis of lymphoma cells and their engulfment by SS-
TAMs in situ was confirmed by immunohistochemistry (IHC;
Figure S1). We first assessed whether apoptosis in lymphoma
cells affects tumor growth. Suppression of apoptosis in BL
cells through expression of anti-apoptotic Bcl-2 or Bcl-xL pro-
moted survival and expansion of transduced cell populations
in vitro (Figure 1B). We previously demonstrated that expres-
sion of these proteins suppresses spontaneous and inducible
apoptosis of lymphoma cells [18]. Remarkably, growth in vivo
was not similarly improved by apoptosis suppression. In xeno-
grafts, apoptosis-suppressed BL cells showed no preferential
capacity to form tumors, instead displaying an equivalent or
slightly slower growth trend as compared to their ‘‘pro-
apoptotic’’ parental counterparts (Figure 1C). Apoptosis-sup-
pressedBL populationsweremarkedly constrained in their ca-
pacity to proliferate in situ, displaying approximately half the
levels of Ki67-positive cells as the parental populations in
which apoptosis occurred constitutively (Figures 1D and 1E).
These results indicate that suppression of apoptosis promotes
autonomous survival of lymphoma cells but compromises
additional pro-tumor mechanisms, which are otherwise gener-
ated by apoptotic B lymphoma cells in vivo.
Apoptosis of B Lymphoma Cells Promotes Tumor
Angiogenesis
Levels of HIF-1a were substantially lower in apoptosis-prone
parental tumors, as compared to their Bcl-2-expressing coun-
terparts (Figure 2A), suggesting that the former tumors were
less hypoxic than the latter. Therefore, we investigated
whether apoptosis promotes angiogenesis. We observed sub-
stantially reduced angiogenesis in apoptosis-suppressed xe-
nografts as demonstrated by CD31+ endothelial cell density
(Figure 2B). A strong association in BL2-Bcl-2 tumors between
proliferation and CD31+ endothelial cell density was also
evident (Figure 2C).
These results suggest that suppression of apoptosis in BL
cells constrains the tumor cell population’s capacity to prolif-
erate in vivo at least in part through reduced angiogenesis.
We propose that hypoxia acts as a trigger for apoptosis
in parental lymphoma cells but causes growth arrest in
apoptosis-suppressed cells. In support of this, parental BL
cells were induced into apoptosis under hypoxic conditions
in vitro, whereas their Bcl-2-overexpressing counterparts sur-
vived better but underwent cell-cycle arrest (Figures 2D–2F).
Apoptosis Promotes Macrophage Accumulation in
Starry-Sky NHL
We hypothesized that the tumor-promoting and pro-angio-
genic effects of apoptosis are due in part to activation of
macrophages by apoptotic lymphoma cells. We determined
whether apoptosis plays a role in controlling TAM accumula-
tion in lymphomas. Observations of biopsies from BL patients
showed that frequencies of apoptotic cells and TAMs were
closely correlated (Figures 3A and 3B). In xenografts, sup-
pression of apoptosis by Bcl-2/Bcl-xL resulted in substantial
reduction (though not abolition) of apoptosis. Parallel reduc-
tion in TAM density was also observed in apoptosis-inhibitedtumors (Figures 3C–3I). This was unlikely to have been due to
the apoptosis suppressors acting on alternative, apoptosis-in-
dependent mechanisms such as macrophage chemoattrac-
tant production (Figure S2).
To understand the mechanisms underlying TAM accumula-
tion, we next tested the effect of liposomal clodronate, which is
known to reduce tissue macrophage numbers through
blockade of blood-monocyte recruitment [19]. Intravenous
liposomal clodronate failed to deplete TAMs despite depleting
splenic macrophages effectively (Figure 3J). Moreover, we
found significant numbers of proliferating TAMs in parental xe-
nografts (Figure 3K). Notably, xenografts in which apoptosis
was suppressed by Bcl-2 displayed substantially less prolifer-
ation of all host cells (Figure 3L).
These results show that SS-TAM accumulation, in part
occurring via macrophage proliferation in situ, is promoted
by constitutive lymphoma cell apoptosis, which is coupled to
enhanced tumor growth and angiogenesis.
Multiple Pro-tumor Pathways Are Activated in SS-TAMs
Since tumor cell apoptosis caused the accumulation of SS-
TAMs, we reasoned that apoptotic lymphoma cells further
engage with SS-TAMs to activate diverse tumor-growth-pro-
moting pathways. Since macrophages are highly responsive
to their environments, we decided against isolating SS-
TAMs, which risks changing their transcriptional profile during
the necessary tissue destruction processing. Rather, we
investigated global gene expression signatures of undisturbed
SS-TAMs in their natural habitat. We adopted laser-capture
microdissection of individual SS-TAMs in BL xenografts in or-
der to obtain unbiased in situ transcriptional profiles of these
cells, which we compared specifically with those of similarly
captured macrophages, the tingible-body macrophages from
normal germinal centers (GCMs) (Figure S3A). The rationale
for this comparison was based upon BL being a germinal cen-
ter malignancy and tingible-body macrophages being re-
garded as normal equivalents of SS-TAMs.
Scatterplot analyses of microarray data (Figure 4A) indi-
cated that, when SS-TAMs were compared with GCMs, 398
genes were upregulated and 997 were downregulated. In
accordance with previously proposed paradigms for macro-
phage activation in tumors, the transcriptome of SS-TAMs
in parental BL xenografts was found to reflect an anti-inflam-
matory, reparatory pro-angiogenesis and tissue-remodeling
activation state (selected genes from microarrays are shown
in Table 1; validation by qPCR is shown in Figures 4B and
S3). Fidelity of macrophage transcripts obtained via laser-cap-
ture microdissection was confirmed (Figures S3B and S3C).
Several of the genes associated with the IL-4Ra-dependent
‘‘alternative activation’’ state, including ARG1, were either
not expressed or only expressed at low levels by SS-TAMs
(Figure 4C). Others were markedly upregulated, notably
CD206 (MRC1), which showed the highest relative expression
(38-fold increase compared to GCMs) in SS-TAMs (Table 1,
asterisks).
Network analysis [23, 24] indicated that SS-TAMs exhibited
features of various macrophage types and activation states,
including peritoneal and bone marrow-derived macrophages
(Figure S3D). Examination of the most highly expressed tran-
scripts identified enrichment of numerous functional pathways
in SS-TAMs that were mainly associated with enhanced
phagocytic capacity, elevated lipid metabolism, matrix re-
modeling, and wound healing (Figures S3E and S3F). The
phagocytic pathway results confirm the active clearance of
Figure 1. Suppression of Apoptosis in Lymphoma Cells
Constrains In Vivo Proliferation and Angiogenesis
(A) Representative H&E staining of tumors from BL
patient (left) and SCID/BL2 xenograft (right) (n = 6).
Arrows exemplify SS-TAMs.
(B) Expression of exogenous Bcl-2 or Bcl-xL promotes
expansion of BL2 cells in vitro. Means 6 SEM (n = 3).
**p = 0.0025, *p = 0.0328. Under normal growth condi-
tions, typically, BL2 cultures are 90%, BL2-Bcl-2 cultures
are 95%, and BL2-Bcl-xL cultures are 93% AxV
2PI2.
(C) Bcl-2 or Bcl-xL gene expression fails to enhance BL2
xenograft growth rate. Mean days for tumor growth to
1.44 cm2 + SEM (left) and growth plots of all tumors
(right) are shown; BL2 (n = 12), BL2-Bcl-2 (n = 8), BL2-
Bcl-xL (n = 8). *p = 0.0444.
(D and E) Proliferation of BL is decreased in BL2-Bcl-2
and BL2-Bcl-xL xenografts. Example of Ki67 IHC in
each type of xenograft tumor is shown in (D). Quantifica-
tion of Ki67 IHC in xenografts showing percent of Ki67+
cells per field + SEM (BL2 and BL2-Bcl-2: n = 8; BL2-
Bcl-xL: n = 3) is shown in (E). **p = 0.0014 BL2-Bcl-2;
**p = 0.0095 BL2-Bcl-xL.
579apoptotic cells by these macrophages that is evident in the
histological picture. Genes encoding receptors, bridging mol-
ecules and anti-inflammatory mediators known to be involvedin recognition of and responses to apoptotic
cells, were among the transcripts most highly
enriched in SS-TAMs. These include MSR1,
CD36, LRP1, CD93, MERTK, GAS6, TREM2,
PPARg, and the most renowned anti-inflam-
matory mediator produced by phagocytes in
response to apoptotic cells, TGF-b1 (Table 1).
Strikingly, strong expression of genes en-
coding growth factors IGF-1 and PDGF-CC
(Table 1), which have been shown potently to
protect cells from apoptosis [25, 26], firmly
indicates that SS-TAMs provide trophic cues
in the lymphoma microenvironment with the
potential to promote net population growth.
In accordance with their multi-functional
tumor-promoting capacity, SS-TAMs were
further found to highly express genes with
capacity to promote angiogenesis and matrix
remodeling (Table 1; Figures 4B and S3C),
including transcripts encoding MMP2, 3, and
12, TIMP-2, CD13, galectin-3, heme oxygen-
ase-1, and GPNMB, which are strongly impli-
cated in these processes [27–30].
Apoptotic Lymphoma Cells Drive
Macrophage MMP2 and MMP12 Expression
We next studied the relationship between lym-
phoma cell apoptosis and TAM activation.
With reference to selected genes from the un-
biased profiling of SS-TAMs from parental BL
xenografts, we found that the activation pro-
files of TAMs from parental as compared to
Bcl-2 tumors were similar (Figures 4D and
S4). Therefore, since apoptosis was reduced
rather than abolished, in Bcl-2-overexpressing
BL tumors (Figures 3E, 3F, and 3I), the (albeit
smaller) contingent of TAMs in these tumors
could be activated similarly to parental SS-TAMs via interaction with the smaller numbers of apoptotic
cells present. Alternatively, the activation status of accumu-
lated TAMs could be influenced by apoptosis-independent
Figure 2. Apoptosis of Lymphoma Cells Promotes Tu-
mor Angiogenesis
(A) Representative HIF-1a IHC of xenograft tumors, BL2
(left) and BL2-Bcl-2 (right) (n = 5–6).
(B and C) Reduced angiogenesis in tumors with sup-
pressed apoptosis is associated with low cell prolifera-
tion. Quantification of CD31 IHC in BL2 and BL2-Bcl-2
xenograft tumors (mean pixels2 per field + SEM; n =
3–5) is shown (B). *p = 0.0184. Quantification of CD31
staining (pixels2 per field6 SEM) in BL2-Bcl-2 xenograft
tumors in areas with high and low Ki67 expression
(% per field 6 SEM; n = 5; **p = 0.0061) is shown (C).
(D and E) Hypoxia induces apoptosis in BL2 cells (D),
whereas apoptosis-inhibited BL2-Bcl-2 cells survive
but undergo growth arrest (E) in vitro. Mean 6 SEM of
three independent experiments.
(F) Representative flow cytometric cell-cycle profiles of
viable-gated BL2-Bcl-2 cells cultured for 48 hr (repre-
sentative of three independent experiments).
580properties of the lymphoma cells. In order to differentiate be-
tween these possibilities, we compared co-culture of macro-
phages in vitro with viable versus apoptotic lymphoma cells.We chose to investigate macrophage gene
expression associated with matrix degrada-
tion—a significant facet of tumor growth and
progression—since no relationship between
the latter and macrophage interaction with
apoptotic cells has been previously estab-
lished. We observed marked upregulation of
both MMP2 and MMP12 by apoptotic lym-
phoma cells (Figures 4E–4I). Viable lymphoma
cells may also contribute to MMP2 and
MMP12 upregulation, but it is noteworthy
that ‘‘viable’’ populations contained small
numbers of constitutively apoptotic cells.
Apoptosis Promotes Tumor Growth in an
Alternative Model of Aggressive NHL
Wewished to determine whether the principle
of tumor cell apoptosis as a promoter of
tumor growth could be extended to other
models. We first investigated a model of
aggressive B cell lymphoma in immuno-
competent mice, l-MYC lymphoma [31],
which also displays starry-sky features with
frequent TAMs and apoptotic events (Fig-
ure 5A). The use of a starry-sky lymphoma
model in immunocompetent, wild-type (WT)
mice additionally provided the opportunity
to study the role of IL-4Ra, since several of
the genes upregulated in SS-TAMs were IL-
4Ra dependent (Table 1, asterisks). We
derived and selected l-MYC B lymphoma
lines that, like the BL lines, retained the
phenotypic characteristics, including pro-
apoptotic propensity, of the tumor biopsy
cells. When grafted to WT mice, these lines
formed rapidly growing tumors (Figure 5B,
upper panel). Upon removal of apoptotic
cells from the transplant inoculum, we
observed delayed or inhibited tumor growth
(Figure 5B). Conversely, UV irradiated(apoptosis-committed) l-MYC cells admixed with viable lym-
phoma cells in the transplant inoculum promoted tumor
growth (Figures 5C and 5D). Despite no significant differences
Figure 3. Apoptosis of Lymphoma Cells Promotes Macrophage Accumulation in Starry-Sky NHL, and This Is Associated with Macrophage Proliferation
(A and B) Correlation between apoptosis and TAM accumulation in human BL. CD68 (TAM) and TUNEL (apoptosis) staining of BL biopsy is shown (A). Linear
correlation of frequencies of CD68+ cells and TUNEL+ cells in BL (means per field; biopsies from six patients) is shown (B).
(legend continued on next page)
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582in accumulating TAMs in WT animals, IL-4Ra2/2 mice dis-
played delayed tumor growth (Figures 5B and 5E). Most strik-
ingly, the combination of removal of apoptotic lymphoma cells
from the graft inoculum together with IL-4Ra deficiency led to
the most marked inhibitory effect on tumor growth and also to
a significant reduction in TAM accumulation (Figure 5B, lower
panel).
Like BL cells, l-MYC lymphoma cells, especially when
apoptotic, were able to activate MMP2 and MMP12 expres-
sion in macrophages in vitro (Figures 5F–5H) and promote
the expression of a variety of SS-TAM markers in bone
marrow-derived macrophages (BMDMs) (Figures S5A and
5I). Furthermore, exposure of classically activated BMDMs to
apoptotic cells inhibited production of pro-inflammatory cyto-
kines (Figures S5B and S5C). Notably, none of the modulatory
effects induced by apoptotic lymphoma cells required macro-
phage IL-4Ra, indicating that the tumor-promoting effects of
apoptotic l-MYC cells and global IL-4Ramay be independent.
This possibility is supported by the additive inhibitory effects
on tumor growth and macrophage accumulation observed
both when apoptotic cells are removed from the graft and
when IL-4Ra is deficient in the host (Figure 5B).
Apoptosis Triggers Direct Activation of MMP2 and MMP12
in B Lymphoma Cells
Given the pleiotropic functions of MMPs in tumor growth and/
or progression and the consistent upregulation of MMP2/12
in macrophages exposed to apoptotic lymphoma cells, we
begananalyzing theexpressionandprocessingofmacrophage
MMP2 and MMP12 at the protein level. Remarkably, in the
course of these studies, we observed that apoptotic lymphoma
cells directly upregulated and processed MMP2 and MMP12
polypeptides in the absence of other cell types in both murine
and human models (Figures S5D–S5F). These results illustrate
that the apoptosis programof lymphoma cells has the potential
to drive tumor progression via MMP2/12 activation not only
through TAM accumulation and activation but also via alterna-
tive mechanisms based on production and processing of these
MMPs directly by the apoptotic lymphoma cells.
Apoptosis Promotes Tumor Growth in a Non-lymphoma
Model
Since apoptosis is linked to poor prognosis in a range of
cancer types, we determined in principle whether apoptosis-
driven tumor growth is restricted to NHL or whether it
has a more general cancer-promoting role. We therefore
analyzed the effect of tumor cell apoptosis on tumor
growth in B16 melanoma. The presence of apoptotic tumor
cells in the transplantation inoculum greatly enhanced the(C–E) Parallel loss of starry-sky morphology, macrophage accumulation, and a
chemical comparisons of starry-sky macrophages (H&E) (D), apoptosis (TUNEL
and F4/80) (E) (n = 3–5; ***p < 0.0001 H&E; **p = 0.0061 TUNEL; **p = 0.0061 a
means + SEM) are shown.
(F) Linear correlation of frequencies of TAMs (CD68+ cells) and apoptotic (TU
n = 17). ***p < 0.0001.
(G–I) Coordinated reduction of apoptosis and TAM accumulation in Mutu I BL
panels) and for TAM accumulation (F4/80-FITC IHC) (G, lower panels) is show
staining, I) (n = 3). Means + SEM are shown.
(J) Morphometric analysis of F4/80 IHC to determine frequency of F4/80+ cells
control liposome-treated mice (n = 3). Means + SEM; *p = 0.0404.
(K) Dual IHC of BL2 xenograft tumors for host Ki67+ (red) and F4/80+ (green) s
(n = 3).
(L) Mouse Ki67 IHC showing reduced incidence of Ki67+ host cells in apoptosis
staining for Ki67 and F4/80 showed 93.98% 6 1.3% (mean 6 SEM) of proliferaaggressiveness of this tumor in a dose-dependent manner
(Figures 6A and 6C) without changing the architecture of the
tumor (Figure 6D). Similarly enhanced aggressiveness was
observed when viable peritoneal macrophages, which share
certain transcriptional features with SS-TAMs (Figure S3D),
were mixed with the tumor inoculum (Figure 6B). B16
melanomas harbored numerous CD206+ TAMs (Figure 6E),
although significant differences in TAM numbers between tu-
mors produced in the presence or absence of admixed tumor
cells were not observed (Figures 6D–6F). These results indi-
cate that apoptosis of tumor cells constitutes a mechanism
to promote progression of cancer that extends beyond NHL.
Discussion
It has been rigorously established that apoptosis is important
in inhibiting malignant disease [8]. Less intuitively, apoptosis
of tumor cell populations has the potential to contribute to
oncogenic processes through multiple mechanisms based
on several known properties of apoptotic cells, notably those
that affect the tissue microenvironment and the immune sys-
tem [4]. Here, we demonstrate that the constitutive apoptosis
occurring in high-grade B cell lymphoma displays pro-tumor
activities by promoting angiogenesis and the accumulation
of tissue-reparatory and growth-promoting macrophages.
We report the first genome-wide transcriptomics analyses of
tissue macrophages interacting with apoptotic cells in situ,
specifically apoptotic B cells in normal and malignant environ-
ments. Our results demonstrate that apoptosis in high-grade
malignant lymphoma fosters the accumulation of macro-
phages that activate diverse pro-tumor signaling pathways.
We propose that sustained apoptosis of a minor component
of the lymphoma cell population promotes tumor growth
and progression. In this regard, the macrophages respond
to apoptosis in the ‘‘homeostatic mode’’ that is featured in
normal development and tissue repair; in the context of
cancer, this normal host response is ‘‘hijacked’’ for the benefit
of the rogue, malignant tissue. In addition to the effects of
apoptotic lymphoma cells on TAMs, we also report that
apoptosis-induced human and murine lymphoma cells upre-
gulate and process MMP2 and MMP12. While assessment of
the significance of this observation for the oncogenic process
will require substantial further investigation, it is tempting to
speculate that conserved pro-tumor mechanisms can be
generated by activation of the apoptosis program of the lym-
phoma cell. Our findings provide a mechanistic basis for the
strong correlation between high apoptosis index, lack of Bcl-
2 expression, and poor prognosis in NHL, regardless of histo-
logical type [10].poptosis incidence in BL2 xenografts expressing Bcl-2. Quantitative histo-
and active caspase-3 [CASP-3]), and macrophage markers (CD68, CD169,
ctive caspase-3; *p = 0.0152 CD68; **p = 0.0100 CD169; *p = 0.0259 F4/80;
NEL+) cells in BL2, BL2-Bcl-2, and BL2-Bcl-xL xenografts (means per field;
xenograft tumors. Representative H&E for starry-sky appearance (G, upper
n. Morphometric analyses of TAM accumulation (H) and apoptosis (TUNEL
in BL2 xenograft tumors and spleen from clodronate liposome-treated and
howing proliferating (white arrow) and non-proliferating (black arrow) TAMs
-suppressed BL2-Bcl-2 xenografts (n = 5). Means + SEM; **p = 0.0061. Dual
ting host cells in BL2 xenograft tumors were F4/80+.
Figure 4. Pro-tumor Activation Status of SS-TAMs
(A) Scatterplot comparison of mean log fluorescence intensity of each SS-TAM versus each GCM transcript. Gene expression changes within: red lines indi-
cate no change, blue indicates 62-fold changes, and green indicates 64-fold changes (n = 3 animals).
(legend continued on next page)
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Table 1. Selected Transcripts Preferentially Expressed in SS-TAMs as
Compared with GCMs
Gene Protein Fold [ p Value
Genes Associated with Reparatory and Pro-tumor Macrophage
Responses
MRC1* mannose receptor, C type 1 (CD206) 38 <0.0001
ANPEP* alanyl (membrane) aminopeptidase
(CD13)
16.6 <0.0001
GPNMB glycoprotein (transmembrane) NMB
(osteoactivin)
8.8 0.00060
PLAU urokinase plasminogen activator 6.7 0.00011
CTSD cathepsin D 6.4 0.00081
CTSB cathepsin B 5.8 <0.0001
FN1* fibronectin 1 5.7 0.00903
HMOX1 heme oxygenase (decycling) 1 5.5 0.00195
CTSL cathepsin L 5.4 0.00103
PSAP prosaposin 4.2 0.00105
TIMP2* tissue inhibitor of metalloproteinase 2 4 0.00022
MMP12* matrix metalloproteinase 12 3.8 0.04470
MMP3 matrix metalloproteinase 3 3.5 0.04072
IGF1* insulin-like growth factor 1 2.5 0.00014
SEPP1* selenoprotein P plasma 1 2.7 0.00046
EMP1 epithelial membrane protein 1 2.3 0.00018
PDGFC platelet derived growth factor CC 2.3 0.00843
MMP2 matrix metalloproteinase 2 2.1 0.00072
CTSS cathepsin S 2.1 0.00063
LAMP2 lysosomal associated membrane
protein 2
2 0.00016
CCL2* chemokine (C-C motif) ligand 2 2 0.01138
Genes Associated with Macrophage Responses to Apoptotic Cells
MSR1 macrophage scavenger receptor
(CD204)
17 <0.0001
LRP1 LDL receptor-related protein (CD91) 8.4 <0.0001
MERTK c-Mer tyrosine kinase 7.5 <0.0001
CD36 CD36 scavenger receptor 5.9 0.00375
CD93* CD93 receptor 5.9 0.00162
LGALS3 galectin 3 5.2 <0.0001
ABCA1* ATP-binding cassette transporter 5.2 <0.0001
PPARG peroxisome proliferator activated
receptor gamma
4.1 0.00115
AXL* AXL receptor tyrosine kinase 3.9 0.00020
TREM2 triggering receptor expressed on
myeloid cells 2
3.5 <0.0001
GAS6* growth arrest specific 6 2.7 0.00578
TGFB1 transforming growth factor beta 1 2.3 0.00476
Transcripts preferentially expressed in SS-TAMs as compared with GCMs
and associated especially with reparatory and pro-tumor activation states,
including trophic/angiogenesis/remodeling pathways, and engagement
with apoptotic cells are shown here. Asterisks indicate genes also associ-
ated with IL-4Ra-dependent, alternative activation [20–22]. Data are from
three animals.
584This study has focused on B cell lymphoma, but, given the
association of aggressive disease with high apoptosis indices
and macrophage frequency in multiple cancer types [9–14], it
seems likely that the mechanisms reported here will prove(B) Validation of selected genes from SS-TAMs and GCMs by qPCR. Means +
(C) Heat map comparing in situ transcriptome of prototypic alternative activat
(D) Heat map showing Fluidigm gene expression analysis of genes in BL2 comp
(n = 8). Data were normalized to CD68 gene expression.
(E and F) qPCR showing upregulation ofMMP12 (E) andMMP2 (F) mRNA in RAW
lymphoma cells (BL2 apoptosis was induced by serum starvation for 1 hr) (n =
(G) qPCR showing absence ofMMP12 andMMP2mRNA expression in BL2 cel
(H and I) qPCR showing upregulation of MMP12 (H) and MMP2 (I) mRNA in H
lymphoma cells (BL2 apoptosis was induced by serum starvation for 1 hr, 30%–
(+SEM) compared to HMDM control. ***p < 0.001, *p < 0.05 (H); ***p < 0.001, *psignificant in other malignancies, too. Results presented here
using a syngeneic B16 melanoma transplant model extend a
recent report of similar effects in an allogeneic setting [33]
and support the proposition that apoptosis drives pro-tumor
activity outside the lymphoma arena. The importance and
route of apoptosis-driven mechanisms may prove to be
context dependent, with variation between tumor types (and
perhaps individual tumors). For example, constitutive pro-in-
flammatory TAM activation is a feature of the most common
human sarcoma, gastrointestinal stromal tumor (GIST), and
these TAMs constrain tumor growth. However, imatinib-
induced apoptosis of tumor cells in GIST therapy appears to
cause tumor-promoting activation of the TAMs and ultimately
leads to imatinib resistance [34].
Our findings extend the known reparatory, immunosup-
pressive, and anti-inflammatory impacts of macrophages in-
teracting with apoptotic cells [1–4], as well as developmental
consequences of apoptosis such as compensatory prolifer-
ation and apoptosis-induced wound healing and regenera-
tive responses [15], providing a rationale for cell death pro-
moting oncogenic progression or relapse post-treatment.
While anti-cancer therapies that induce apoptosis in tumor
cells drive the cell birth/cell death equation toward cure,
it is becoming clear that apoptosis-inducing therapeutic ef-
fects can lead to tumor re-population [35]. These findings,
taken together with those presented here, emphasize the
need for therapeutic modalities, such as immunogenic tu-
mor cell-death-inducing treatments [36] that simultaneously
activate host anti-tumor responses as well as cell death
pathways.
Although the molecular mechanisms critical for pro-tumor
activation of SS-TAMs by apoptotic cells require further eval-
uation, the present work highlights several candidate onco-
genic players such as galectin-3 and the TYRO/AXL/MER
axis. Intriguingly, it was recently demonstrated in breast can-
cer that the widespread tumor cell death and accompanying
macrophage-mediated clearance and activation, which is
associated with post-partum mammary gland involution, pro-
moted tumor metastasis and was dependent upon MER tyro-
sine kinase [37].
Angiogenic and growth/survival factors such as IGF-1 are
induced in SS-TAMs, and our results are consistent with tumor
cell apoptosis caused by hypoxia or growth/survival factor
deprivation promoting angiogenesis or trophic factor produc-
tion via TAM activation. Our investigations into the IL-4/IL-13
axis indicated that global expression of IL-4Ra was required
for optimal pro-tumor effects of apoptotic lymphoma cells, as
well as optimal TAM accumulation (Figure 5B). The apoptotic
cells were capable of directly activating macrophages in vitro
toward a pro-tumor phenotype (and away from an anti-tumor
pro-inflammatory state) in the absence of IL-4Ra. This sug-
gests that the role of the IL-4/IL-13 axis in the pro-tumor effects
of apoptosis is distinct from the IL-4Ra-dependent, alternative95% confidence intervals for n = 2.
ion gene signatures of SS-TAMs and GCMs (n = 3 animals).
ared to BL2-Bcl-2 xenograft formalin-fixed, paraffin-embedded tumor tissue
264.7 macrophages following co-culture with viable or apoptotic (apo) BL2
3). ***p < 0.001 (E); ***p < 0.001 (F). Means + SEM.
ls. Data were normalized to expression by THP-1 cells (n = 3). Means + SEM.
MDM macrophages following co-culture with viable or apoptotic (apo) BL2
39%AxV+/PI-) (n = 3). RelativemRNA expression shown ismean fold change
< 0.05 (I).
Figure 5. The Growth of Syngeneic l-MYC Transplanted Tumors Can Be Modified by Regulation of Tumor Cell Apoptosis
(A) Typical starry-sky histology in syngeneic l-MYC transplanted tumors in C57BL/6 mice. Representative H&E-stained, CD68-stained, F4/80-stained, and
active caspase-3-stained sections are shown.
(legend continued on next page)
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Figure 6. Apoptosis Promotes Tumor Growth in a
Non-lymphoma Model
(A–C) Kaplan-Meier plots for C57BL/6 mice
following transfer of 6 3 104 viable B16 cells
alone and co-injected with irradiated B16 cells
(103 106) (A), syngeneic peritoneal macrophages
(B), and irradiated B16 cells (various doses up to
10 3 106) (C). Irradiated B16 cells underwent
apoptosis in vitro as described previously [32]
and failed to grow in vivo (data not shown). p =
0.031, n = 5 (A); p = 0.018, n = 6 (B); irradiated
B16 cells, 0.1 3 106: p = 0.0022, 1 3 106: p =
0.0011, 10 3 106: p = 0.0009, n = 6 (C).
(D) H&E staining of B16 melanoma tumors gener-
ated by injection of 63 104 viable cells6 103 106
irradiated B16 cells.
(E) Representative image of CD206 IHC in B16
melanoma.
(F) Morphometric analysis of CD206 IHC in B16
melanoma generated by injection of 6 3 104
viable cells with various numbers of irradiated
cells (means + SEM; n = 3–5).
586macrophage activation pathway. A similar activation signature
that was distinct from alternative macrophage activation (with
the notable exception of MRC1) was recently reported for
TAMs in a breast cancer model [6]. Taken together with our
observation that apoptotic cells and IL-4Ra have additive
effects in promoting tumor growth (and macrophage accumu-
lation), our results are consistent with roles for IL-4/IL-13
in driving NHL-promoting mechanisms independently of
apoptosis. Our findings (Figures 5 and S5) strongly indicate
that apoptotic lymphoma cells do not activate macrophages
via this route. This conclusion is further supported by our ob-
servations that neither human nor murine NHL cells studied
here secreted IL-4 or IL-13 either constitutively or following in-
duction of apoptosis.(B) Syngeneic l-MYC lymphoma growth and incidence of F4/80+ TAM inWT and IL-4RaKO. C57BL/6mice
presence of 3.13 106 (mock-depleted sample) or 0.33 106 (depleted sample) apoptotic l-MYC cells (n =
for F4/80; means + SEM). **p = 0.0061.
(C) Kaplan-Meier plots for C57BL/6 mice following transfer of 13 105 viable l-MYC cells alone, co-injecte
cells or UV-irradiated cells alone (six animals per group). **p = 0.0076.
(D) UV-irradiated l-MYC cells underwent apoptosis in vitro as assessed by AxV/PI staining. Means + SE
(E) Morphometric analysis of resultant l-MYC tumors immunostained for CD206-expressing cells (mean
observed.
(F–H) qPCR showing upregulation ofMMP12 (F) (***p < 0.001) andMMP2 (G) (***p < 0.001, **p < 0.01, *p <
co-culture with viable or apoptotic (apo) l-MYC (l-MYC) lymphoma cells (l-MYC apoptosis was induced
30%) (n = 3).MMP12 andMMP2mRNA was restricted to the macrophages in the co-cultures since little
real-time qPCR (H). Data were normalized to TUBA1B endogenous levels. All values are means + SEM o
(I) WT versus IL-4Ra KO BMDM responses to apoptotic l-MYC cell co-culture. BMDM from WT or IL-4R
apoptotic l-MYC cells. Apoptosis of l-MYC cells was triggered by 100mJ UVB irradiation. mRNA express
culture and normalized using HSP90, TUBA1B, and HPRT. Expression is presented as mean fold changeGiven the heterogeneity of tumor cell
populations and stromal elements in
cancer together with the plasticity of
tissue macrophages, it is not surprising
that signatures of TAMs in different
tumor types have not proved entirely
consistent, although the general para-
digm of activation toward a repara-
tory, anti-inflammatory gene expres-
sion pattern holds for tumor-promoting
TAMs in different models. It seems
reasonable to assume that specific
activation pathways are likely to beimportant for some tumors, but not others. Thus, it has
recently been proposed for certain syngeneic transplantable
solid murine tumors that lactate production by the tumor cells
generates a conserved, ‘‘alternative activation-like’’ TAM sig-
nature that is orchestrated by HIF-1a and characterized by
arginase-1 and VEGF activation [7]. In our xenograft model,
we found neither arginase-1 (Figures 4C and S4B) nor VEGF
(unpublished data) to be activated in SS-TAMs. The extent to
which lactate plays a role in activating TAMs in NHL remains
to be determined, as does the generality and molecular detail
of the apoptosis-driven TAM activation mechanism(s).
The results presented here raisemany questions concerning
the impact of cell death—either that of the constitutive fraction
of growing tumor cells or that induced by therapy—on thereceived 53 106 viable l-MYCcells at day 0 in the
5–6 animals for tumor growth and n = 3–5 animals
d with 13 107 UV-irradiated (200 mJ/cm2) l-MYC
M for three independent experiments.
s + SEM; n = 5). No significant differences were
0.05) mRNA in RAW264.7 macrophages following
by serum starvation for 1 hr, AxV+/PI- cells 25%–
or no expression was detected in l-MYC cells by
f three independent experiments.
a KO C57BL/6 mice were co-cultured for 24 hr 6
ion of selected genes was assessed following co-
+ SEM compared to BMDM control.
587pathogenesis of cancer and on the role of macrophages in
promoting tumor growth. Furthermore, the tumor-promoting
mechanisms emanating from apoptosis of transformed cells
may significantly influence other immune and non-cancerous
host cells as well as transformed relatives (notably cancer
stem cells). It is well established that mitogenic signals,
such as Wnt, Hedgehog, and prostaglandin E2, are produced
by apoptotic cells of diverse metazoans during develop-
ment, in response to injury and during regeneration, including
re-population of tumors after radiotherapy [15, 35, 38].
Given the observed mechanistic similarities between cancer,
wound healing, and tissue regeneration, it seems likely that
apoptosis may play related roles in all three. It is already clear
that apoptosis-induced compensatory proliferative mecha-
nisms are variable and context dependent. Therefore, the
apoptosis-mediated mechanisms relevant to tumor evolution
and growth seem likely to be similarly complex. Our results
demonstrate that responses of phagocytes are a key part of
this complexity (as previously proposed [4, 39]) and that cell
death and tissue remodeling are closely interwoven in NHL.
Further research will be required to investigate these new di-
rections, and, based on the present findings, a full understand-
ing of the pro-tumor effects of apoptosis in different types of
cancer is warranted.
Experimental Procedures
Experimental protocols including in situ transcriptomics methods devel-
oped for these studies are detailed in the Supplemental Information.
Statistics
Statistical significance was determined using Wilcoxon matched pairs (Fig-
ure 3H), Mann-Whitney nonparametric tests (Figures 1B, 1C, 1E, 2B, 2C, 3D,
3E, 3J, 3L, and 5B), or one-way ANOVA followed by Tukey-Kramer post-test
(Figures 4E, 4F, 4H, 4I, 5F, and 5G). Statistical significance of gene expres-
sion analyses was tested using LIMMA software or the Benjamini and Hoch-
berg procedure for multiple testing corrections. Significance is represented
as *p < 0.05, **p < 0.01, and ***p < 0.001. Kaplan-Meier plots were compared
using the Mantel-Cox log rank test (Figures 5C and 6A–6C). For animal
studies, sample sizes were guided by previous experimentation [16, 40, 41].
Accession Numbers
The GEO [42] accession number for the microarray data reported in this pa-
per is GSE64366.
Supplemental Information
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cub.2014.12.059.
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